Real-world study assessing Efficacy of TezepeLumaB in patients with severe asthma regardless of phenotype in Russia

Trial Identifier: D5180R00029
Sponsor: AstraZeneca
Start Date: September 2024
Primary Completion Date: September 2026
Study Completion Date: September 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Ekaterinburg, Russia
Russia Kaliningrad, Russia
Russia Kemerovo, Russia
Russia Krasnodar, Russia
Russia Moscow, Russia
Russia Nalchik, Russia
Russia Nizhny Novgorod, Russia
Russia Novosibirsk, Russia
Russia Orenburg, Russia
Russia Petrozavodsk, Russia
Russia Saint-Petersburg, Russia
Russia Shelehov, Russia
Russia Stavropol, Russia
Russia Tomsk, Russia
Russia Ulan-Ude, Russia